Group 1 - The core point of the article is that 合富中国 (603122.SH) reported a decline in consolidated revenue for the first seven months of 2025, amounting to RMB 425 million, which represents a decrease of 22.66% compared to the same period last year [1] - For the first six months of 2025, the consolidated revenue also showed a decline of 23.53% year-on-year, although the rate of decline has narrowed by 0.87%, indicating a continuous improvement in revenue situation [1]

Group 1 - The core point of the article is that HeFu China (603122) reported a decline in consolidated revenue for the first seven months of 2025, amounting to 425 million yuan, which represents a decrease of 22.66% compared to the same period last year [1] - For the first six months of 2025, the consolidated revenue also showed a decline of 23.53% year-on-year, although the rate of decline has narrowed by 0.87%, indicating a continuous improvement in revenue situation [1]

据合富中国公告，公司2025年1-7月合并营业收入人民币42,512.74万元，较去年同期下降 22.66%，2025 年 1-6 月合并营业收入较去年同期下降23.53%，下降幅度收窄 0.87%，营收情况持续改善。 ...

[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates a loss for the first half of 2025, with net profit attributable to owners of the parent company projected to be between -9.0 million RMB and -6.3 million RMB Estimated Performance Indicators | Performance Indicators | Estimated Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Owners of the Parent Company | -9.0 million to -6.3 million | | Net Profit Attributable to Owners of the Parent Company After Deducting Non-Recurring Gains and Losses | -8.72 million to -6.02 million | [Prior Period Operating Performance and Financial Position](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5) Contrary to the current period's projected loss, the company achieved profitability in the prior period (first half of 2024), with net profit attributable to owners of the parent company at 22.5219 million RMB Prior Period Performance Indicators | Performance Indicators | Amount (RMB) | | :--- | :--- | | Total Profit | 31.2322 million | | Net Profit Attributable to Owners of the Parent Company | 22.5219 million | | Net Profit Attributable to Owners of the Parent Company After Deducting Non-Recurring Gains and Losses | 20.7641 million | | Earnings Per Share | 0.06 RMB/share | [Primary Reasons for Current Period's Projected Loss](index=2&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E4%BA%8F%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) The current period's projected loss is primarily due to declining sales revenue and gross profit, increased R&D and market investment, exchange losses, and a slower reduction in expenses - Sales revenue and gross profit simultaneously declined due to the domestic macroeconomic environment and policies such as centralized procurement price reductions, leading to lower hospital client purchase prices and reduced order volumes[8](index=8&type=chunk) - To adapt to market changes, the company adjusted its business layout, continuously investing resources in the iterative R&D, production, and market development of its proprietary "ACME" product[8](index=8&type=chunk) - The appreciation of the New Taiwan Dollar resulted in exchange losses for the company, negatively impacting net profit[8](index=8&type=chunk) - Despite implementing expense controls, the short-term decrease in administrative and selling expenses was less than the reduction in revenue, contributing to the performance decline[8](index=8&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company explicitly states that this performance forecast data is a preliminary calculation and has not been audited, with the final accurate financial data to be released in the official 2025 semi-annual report - This performance forecast has not been audited by a certified public accountant, and the final accurate data will be based on the company's officially disclosed 2025 semi-annual report[9](index=9&type=chunk)[10](index=10&type=chunk)

合富中国（603122）公告，预计2025年半年度归属于母公司所有者的净利润为-900万元到-630万元，与 上年同期相比，将出现亏损。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益后的净利 润为-872万元到-602万元。 ...

合富（中国）医疗科技股份有限公司董事会 2025 年 7 月 11 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司 营业收入。本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据 以公司定期报告为准，敬请投资者注意投资风险。 公司 2025 年 1-6 月合并营业收入人民币 36,765.82 万元，较去年同期下降 23.53%，2025 年 1-5 月合并营业收入较去年同期下降 24.15%，下降幅度收窄 0.62%，营收情况持续改善。 特此公告。 证券代码：60312 ...

Core Viewpoint - 合富中国 reported a consolidated revenue of 368 million yuan for the first half of 2025, representing a year-on-year decline of 23.53% [1] Revenue Performance - The revenue for the first five months of 2025 showed a year-on-year decline of 24.15%, indicating a slight improvement in the revenue trend as the decline narrowed by 0.62% [1]

Core Points - The stock price of HeFu China (603122) increased by 2.07% to 6.89 CNY as of July 4, 2025, with a market capitalization of 2.743 billion CNY [1] - The company completed the cancellation of its initial public offering (IPO) fundraising account, with a total fundraising amount of 416.96 million CNY and a net amount of 359.69 million CNY after expenses [1][2] - HeFu China announced a cash dividend of 0.13 CNY per share for the 2024 annual equity distribution, totaling 51.75 million CNY [3] Company Announcements - HeFu China has completed the cancellation of its IPO fundraising account, with the balance of 58.45 million CNY transferred to the general account [2] - The company signed a tripartite supervision agreement regarding the fundraising account and later terminated it after the account's cancellation [2] - The cash dividend distribution was approved at the annual shareholders' meeting on June 25, 2025, with specific tax implications for different types of shareholders [3]

Core Viewpoint - The company has completed the cancellation of its fundraising special accounts, following the approval of its fundraising management and usage protocols, ensuring compliance with regulatory requirements [1][2][3]. Fundraising Basic Information - The company raised a total of RMB 416,960,308.00 through its initial public offering of 99,513,200 shares at a price of RMB 4.19 per share, with all funds received by February 11, 2022 [1]. Fundraising Management and Storage - The company established a fundraising management system to ensure proper storage and usage of the raised funds, signing a tripartite supervision agreement with relevant banks and its sponsor [2]. - A quadripartite supervision agreement was later signed to allow the company to provide loans to its wholly-owned subsidiary for project implementation [2]. Fundraising Account Cancellation - The company decided to open a new special account for fundraising to improve the yield of the raised funds and subsequently canceled the previous accounts, with the cancellation process completed by March 11, 2025 [3][4]. - The total balance of the canceled fundraising accounts was transferred to the new account, and all relevant agreements were terminated [4].

证券代码：603122 证券简称：合富中国 公告编号：临 2025-029 合富（中国）医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.13元 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/11 | － | 2025/7/14 | 2025/7/14 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 6 月 25 日的2024年年度股东会审议通过。 本次利润分配以方案实施前的公司总股本398,052,633股为基数，每股派发现金红利0.13 元（含税），共计 ...